Last reviewed · How we verify
SC0245
At a glance
| Generic name | SC0245 |
|---|---|
| Also known as | SC0245 tablet |
| Sponsor | Biocity Biopharmaceutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC0245 CI brief — competitive landscape report
- SC0245 updates RSS · CI watch RSS
- Biocity Biopharmaceutics Co., Ltd. portfolio CI